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Detection of gene amplification in MYCN, C-MYC, MYCL1, ERBB2, EGFR,
AKT2, and human papilloma virus in samples from cervical smear normal
cytology, intraepithelial cervical neoplasia (CIN I, II, III), and cervical cancer*
 DABEIBA ADRIANA GARCÍA, MSC1, IGNACIO BRICEÑO, PhD2,
MARCOS CASTILLO, MD2, FABIO A. ARISTIZÁBAL, PhD3
SUMMARY
Introduction: Cervical cancer is the second most common cancer among women worldwide and the second cause of
cancer mortality in women. It has been demonstrated that the process of cervical carcinogenesis displays genetic and
environmental epigenetic components. Currently, research is focused on new prognosis markers like oncogene amplification.
Objectives: To perform detection of MYCN, C-MYC, MYCL1, ERBB2, EGFR, and AKT2 amplification. Additionally,
to detect human papillomavirus in samples from normal cytology smear, cervical intraepithelial neoplasia (CIN) I, II, and III
and cervical cancer patients.
Methods: Papillomavirus (HPV) genotyping by reverse line blot (RLB) performed and gene amplification by detection
with real-time PCR with Taqman probes.
Results: HPV was present in 4% of the patients with normal cytology, 48% in CIN I, 63.6% in CIN II, 64% in CIN III,
and 70.8% in cervical cancer. Genes amplified in cervical cancer were MYCN (39.1%), ERBB2 (34.7%), and MYCL1 (30.4%);
showed higher amplification in high-grade lesions and cervical cancer in relation to low-grade lesions and normal cytology
with statistically significant differences. Besides the genes, C-MYC, EGFR, and AKT2 were amplified in samples from
patients with cervical cancer by 12%, 18%, and 13%, respectively; we did not find statistical differences.
 Conclusion: Higher prevalence of gene amplification and HPV was found in high-grade cervical lesions and cervical
cancer.
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Detección de amplificación en los genes MYCN, C-MYC, MYCL1, ERBB2, EGFR y AKT2 y del virus de papiloma
humano en muestras de cepillado cervical en mujeres con citología normal y con neoplasia intraepitelial cervical
(NIC) I, II, III y cáncer de cuello uterino
RESUMEN
Introducción: El cáncer cervical es el segundo cáncer más importante en mujeres a nivel mundial y es la segunda causa
de muerte por cáncer en mujeres. Se ha demostrado que el proceso de carcinogénesis cervical presenta componentes tanto
genéticos como epigenéticos y medio ambientales. En la actualidad, hay gran interés en la búsqueda de marcadores
moleculares asociados con la progresión de esta enfermedad, uno de los posibles mecanismos y que además está poco
estudiado en cáncer cervical es la amplificación génica de algunos oncogenes como la familia MYC, EGFR y AKT entre otros.
Objetivos: Detectar la amplificación génica de MYCN, C-MYC, MYCL1, ERBB2, EGFR y AKT2 además de la presencia
del virus de papiloma humano en cepillados cervicales en mujeres con citología normal o con neoplasia intraepitelial cervical
(NIC) I, II y III o con cáncer cervical.
Métodos: Se genotipificó mediante reverse line blot (RLB) el virus de papiloma humano (VPH) y se determinó el estado
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de amplificación génica de los genes mencionados mediante
PCR en tiempo real utilizando sondas taqman.
Resultados: El VPH se encontró presente en 4% de las
pacientes con citología normal, en 48% en NIC I, 63.6% en
NIC II, 64% en NIC III y 70.8% en cáncer cervical. Los genes
MYCN, MYCL1 y ERBB2 mostraron mayor amplificación en
lesiones de alto grado y cáncer con diferencias estadística-
mente significativas  a las lesiones de bajo grado y citología
normal, en 39.1%, 34.7% y 30.4% respectivamente. Ade-
más, se encontraron amplificados los genes C-MYC, EGFR
y AKT2, en muestras de pacientes con cáncer cervical, en
12%, 18% y 13% respectivamente. Sin embargo, no se
observaron diferencias estadísticamente significativas con
respecto a las lesiones de alto y bajo grado y citología normal.
Conclusión: En las lesiones de alto grado como en cáncer
cervical, se encuentra mayor prevalencia del virus al igual
que se detectan mayor cantidad de alteraciones genéticas
como la amplificación génica.
Palabras clave: VPH; Amplificación génica; MYCN;
C-MYC; MYCL1; ERBB2; EGFR; AKT2.
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Cervical cancer is one of the most important diseases
worldwide; in Colombia, the estimated incidence is
21.5 cases per 100,000 inhabitants1. The natural biology
of the cervical cancer process begins with noninvasive
squamous lesions that progress to cervical intraepithelial
neoplasia (CIN) I, II, and III. In some cases, the lesions
progress to invasive carcinoma2. However, it is not yet
known what lesions progress and which of them revert
their state, nor the mechanisms of tumor progression in
this type of neoplasia. No one has found a molecular
marker that is significantly associated with the
progression or clinical outcome of the disease.
Among prognostic markers in cervical cancer
amplification, hTERT has been proposed. The gene
amplification activates the oncogenic potential of cellular
protooncogenes, which is a reflection of genetic instability
of tumor cells and is a particular feature of an aggressive
series of tumors3. The term Gene amplification refers to
the increased number of gene copies as a local effect.
Amplification of specific genes has been implicated in an
increasing variety of cell adaptive responses to environ-
mental stress and it is one of the mechanisms by which the
cell responds to the demand for the synthesis of specific
gene in amounts exceeding the transcriptional capacity of
a single copy of a gene4. Amplification is an non-
programmed aberration only seen in response to the
exposure of certain cytotoxic drugs and as an associated
phenomenon with tumorigenesis.
Among the techniques used to detect gene
amplification are fluorescent in situ hybridization
(FISH), array-based comparative genomic hybridization
(array-CGH), and real-time PCR (qPCR). Malakh et
al., in 2008, showed a strong correlation among these
three methods, close to 99%, to detect a number of
MYCN copies of brain cancer5.
In cervical cancer, amplification of the EGFR
oncogene has been observed, which is considered a
marker of poor prognosis, mainly in breast and lung
cancer. Although in cervical cancer only a low
percentage of such is amplified, this amplification
occurs mainly in adenocarcinomas also correlating
with poor prognosis6. Other genes such as C-MYC and
MYCN have been found amplified up to five times more
in 40% of cervical cancer, also suggesting a poor
prognosis7. However, there are few studies evaluating
gene amplification in cervical cancer of genes MYCL1,
ERBB2, and AKT2. For this reason, in this study we
sought to evaluate gene amplification of EGFR, C-
MYC, MYCN, MYCL1, ERBB2, and AKT2 in both
women with normal cytology and patients with
preneoplastic and neoplastic lesions of cervical cancer.
METHODS
 Population and samples. This study is descriptive,
cross-sectional and observational; the number of patients
was defined by convenience sampling and was collected
during an eight-month period in a hospital in the city of
Bogotá. Cervical brush samples were taken by trained
personnel, the patients included in the study were 50
with negative cytological results and 96 patients with
pathologically confirmed diagnosis (25 with CIN I, 22
CIN II, 25 CIN III, and 24 with cervical cancer). These
patients had not started any treatment and agreed to
participate voluntarily in the study by signing an
informed consent.
The cervical smears were taken in 1X PBS and
0.05% thimerosal. The sample was divided into two
aliquots, one of them was centrifuged at 3000 g for 10
minutes, 1 ml of 10 mM tris-HCl buffer (pH 8.3) was
added to the obtained precipitate; after that, the sample
was heated for 10 minutes and centrifuged at 3000 g for
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one minute, the supernatant was used directly to perform
PCR of β-globin and HPV genotyping by Reverse Line
Blot (RLB). In the other aliquot, DNA was isolated by
phenol-chloroform method for analysis of gene
amplification via real-time PCR.
DNA quality. The supernatants of cervical smears
were used as templates to amplify the β-globin gene by
using PCO3 (sense) 5 ‘ACACAACTGTGTTCAC
TAGC 3’ and PCO4 (antisense) 5 ‘CAACTTCATC
CACCTTCACC 3’ primers. The final concentrations
used were 10 mM Tris-HCl, 50 mM KCl, 0.1% triton X-
100, 3 mM MgCl2, 7.5 pmol of each primer, 1 U Taq
polymerase and 200 um of each dNTPs. Amplification
was performed in the thermocycler MyCyclerTM
(BioRad Laboratories, USA), conditions were 1 cycle
at 95°C for 3 minutes and 40 cycles at 95°C for 20
seconds, 58°C for 20 seconds, and 72°C for 20 seconds.
PCR products were analyzed by electrophoresis on 2%
agarose and stained with ethidium bromide 10 mg/ml,
the expected product was 110 bp. The positive control
was lymphocyte DNA with approximately 25 ng, and
PCR mixture as negative control. To find the limit of
detection, dilutions were made in base 2 of lymphocyte
DNA of 25 ng, and found screening to the sixth dilution
equivalent to 390 pg.
HPV genotyping. We used the method described by
Van Der Brule in 20028, which is based on the reverse
hybridization assay, using a miniblotter system on the
PCR product using primers GP5+(S) 5’TTTGTTACT
GTGGTAGATACTA3' and GP6+(A) 5’GAAAAAT
AAACTGTAAATCATA3'+Biotin. This genotyping
method is called Reverse Line Blot (RLB), which
allows identifying 37 HPV genotypes. The specific
viral types were: HPV 6, 11, 16, 18, 26, 31, 33, 34, 35,
39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59,
61, 66, 68, 70, 72, 73, 82, 83, 84, 82, 71, 81, and
CP6108. Plasmids of HPV 16 and HPV 18, donated by
the DKFZ (German Cancer Research Center,
Heidelberg, Germany), were used as positive controls;
the detection limit for these two viral types was 1 fg, and
as a negative control we used the PCR mixture.
Analysis of MYCN, C-MYC, MYCL1, ERBB2,
EGFR, AND AKT2 gene amplification. We designed
the primers and TaqMan probes to amplify each of the
genes (MYCN, C-MYC, MYCL1, ERBB2, EGFR, and
AKT2) and as a reference the Actin (ACTB) gene was
selected by using the Primer ExpressTM software -
Applied Biosystems, Foster City, CA. Table 1 summa-
rizes the sequences of each of the primers and probes
used.
A Taqman® Universal PCR Master Mix (Applied
Biosystems, Foster City, CA) PCR kit was used for
real-time PCR. The final concentrations used were: 1X
Master mix, each primer 50 nm, 50-nm probe, and a
sample using DNA extracted with phenol-chloroform-
isoamyl; each sample was evaluated in triplicate. In the
negative control, water was added to the PCR mixture
instead of the sample.
 PCR conditions were 1 cycle at 95°C for 10 minutes
followed by 40 cycles at 95°C for 15 seconds, 61°C for
1 minute, and 72°C for 20 seconds (Applied Biosystems
7500 Real-Time PCR System). We performed a stan-
dard curve for the actin or reference gene (ACTB) using
base 10 dilutions of DNA from lymphocytes (15 ng to
15 fg); the limit of detection of this gene was 150 fg. The
calculation to determine gene amplification was 2 (actin
CT-CT target gene).
Ethical considerations. The study respected the
ethical and legal aspects of research on human beings,
as stipulated in resolution No. 008430 of 1993 from the
Ministry of Health of the Republic of Colombia and
according to the Helsinki declaration of 1975 as amended
in 2004.
Patients included in this study voluntarily agreed to
participate in the study after reading and understanding
the informed consent, which was approved by the ethics
committee at Colombia’s Universidad Nacional. In
addition, each patient enrolled in the study completed,
with the help of the doctor taking the sample, a survey
that included demographic characteristics and risk
factors associated with the development of cervical
cancer.
Statistical analysis. A database was developed with
information from every patient, in .xls format (Microsoft
Excel®). Information processing was performed by
using a univariate descriptive analysis, making tables
and plots for qualitative variables, such as the presence
or absence of HPV and viral type. The multiple
comparisons among types of injuries and analyzed gene
amplification were performed by using Bonferroni’s
multiple comparison and variance analysis for (one-
way) using the SPSS® software.
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Table 1
Sequence of primers and probes
Gene
      Product
    Size (bp)       Melting
     temp (°C)
MYCN
Sense primer 5´ AGGAAGATGAAGAGGAAGAAATCG 3´  75  72.8
Antisense primer 5´ TGACAGCCTTGGTGTTGGAG 3´
Probe 5´HEX-CGCCGCTTCTCCACAGTGACCACG-TAMRA 3´
C-MYC
Sense primer 5´ TCTACTGCGACGAGGAGGAG 3´  102 78.2
Antisense primer 5´ GCAGCAGCTCGAATTTCTTCC 3´
Probe 5´ROX-ACCAGCAGCAGCAGCAGAGCGA-TAMRA 3´
MYCL1
Sense primer 5´ CCTAAGAGACCTTCAAGCCAGTG 3´  82  73.7
Antisense primer 5´ CCAGATATGGGGCTCATAACACC 3´
Probe 5´ TAMRA - ACCTGGAGACACCTGGACACGCCC - TAMRA´
ERBB2
Sense primer 5´ AGCAGACCCAGTACCTGTCC 3´  141  79.3
Antisense primer 5´ AGGGTTGGTCCTTCTATGAGAAT 3´
Probe 5´HEX-AGTGCCGCTGCTGCTCCGACAAC-TAMRA 3´
EGFR
Sense primer 5´GACCTGGGAGCTGGGAGAAC 3´  97 79.6
Antisense primer 5´ ACCTGCCTTTTGCCAACGAG 3´
Probe 5´ TAMRA-AACTAACCGCCGCCAGCACCACC-FAM 3´
AKT2
Sense primer 5´ AGACCTGGGCTGGTGATGTG 3´  121 79.1
Antisense primer 5´ CAGACTGTGGGACCTTTCTCTC 3´
Probe 5´ROX-ACCACGAGCCACGGAAGCCAGTCA-TAMRA 3´
ACTIN
Sense primer 5´ CCGTCTTCCCCTCCATCGTG 3´  111  84.1
Antisense primer 5´ GGCTCCTGTGCAGAGAAAGC 3´
Probe 5´FAM- TTGCCTCCCGCCCGCTCCCG-TAMRA 3´
 RESULTS
The socio-demographic characteristics and risk
factors associated with the development of cervical
cancer in the population studied are summarized in
Table 2; it was observed that 53.4% of the population
was younger than 34 years of age, and from this
percentage up to 70.5% belonged to groups of women
with normal cytology and patients with CIN I, while
only 10.95% of the population studied were older than
55 years of age; 62.5% of this percentage belonged to
patients with cervical cancer. With regard to the social
stratum, 39.04% belonged to a lower stratum. A total of
46.6% of the population reportedly had their first sexual
relationship when they were less than 18 years of age.
With respect to the number of sexual partners, 66.4% of
the respondents reported having had 1 to 2 partners.
Some 82.2% of the women have been pregnant and
among them 71.9% had their first childbirth when they
were younger than 24 years of age. Finally, 48.6% do
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Table 2
Cervical cancer risk factors; social and demographic characteristics of the population
   Characteristc Normal citology CIN I       CIN II  CIN III          Cancer         Total
    n           %        n        %            n      %         n       %   n       %        n %
Age (years)
       <25 20 40.0 13 52.0 5 22.7 2 8.0 0 0.0 40 27.4
    25-34 18 36.0 4 16.0 7 31.8 7 28.0 2 8.3 38 26.0
    35-44 6 12.0 4 16.0 4 18.2 9 36.0 4 16.7 27 18.5
    45-54 5 10.0 3 12.0 4 18.2 5 20.0 8 33.3 25 17.1
    55-64 1 2.0 1 4.0 2 9.1 2 8.0 7 29.2 13 8.9
       +65 0 0.0 0 0.0 0 0.0 0 0.0 3 12.5 3 2.1
Socioeconomic stratum
    Low 13 26.0 8 32.0 13 59.1 9 36.0 14 58.3 57 39.0
    Medium 26 52.0 16 64.0 6 27.3 14 56.0 9 37.5 71 48.6
    High 11 22.0 1 4.0 3 13.6 2 8.0 1 4.2 18 12.3
1st intercourse (years)
      <18 26 52.0 10 40.0 11 50.0 9 36.0 12 50.0 68 46.6
   18-24 22 44.0 14 56.0 11 50.0 15 60.0 11 45.8 73 50.0
   25-32 2 4.0 1 4.0 0 0.0 1 4.0 1 4.2 5 3.4
Sexual partners
   1-2 27 54.0 18 72.0 13 59.1 20 80.0 19 79.2 97 66.4
   3-4 16 32.0 6 24.0 7 31.8 2 8.0 4 16.7 35 24.0
   5-6 5 10.0 0 0.0 2 9.1 3 12.0 1 4.2 11 7.5
    +7 2 4.0 1 4.0 0 0.0 0 0.0 0 0.0 3 2.1
Pregnancies
  None 10 20.0 7 28.0 5 22.7 3 12.0 1 4.2 26 17.8
   Live
      1-2 24 60.0 15 83.3 8 47.1 12 54.5 4 17.4 63 43.2
      3-4 14 35.0 3 16.7 8 47.1 8 36.4 6 26.1 39 26.7
       +5 2 5.0 0 0.0 0 0.0 1 4.5 13 56.5 16 11.0
   Dead
      1-2 6 15.0 4 22.2 5 29.4 6 27.3 8 34.8 29 19.9
       +3 0 0.0 0 0.0 0 0 0 0.0 2 8.7 2 1.4
1st birth (years)
      <18 13 32.5 4 22.2 4 23.5 5 22.7 10 43.5 36 24.7
   18-24 24 60.0 9 50.0 12 70.6 11 50.0 13 56.5 69 47.3
   25-32 2 5.0 4 22.2 0 0.0 5 22.7 0 0.0 11 7.5
      +33 1 2.5 1 5.6 0 0.0 0 0.0 0 0.0 2 1.4
Contraceptive use
   Yes 28 56.0 18 72.0 14 63.6 11 44.0 4 16.7 75 51.4
   No 22 44.0 7 28.0 8 36.4 14 56.0 20 83.3 71 48.6
Vaginal infection
   Yes 15 30.0 4 16.0 4 18.2 6 24.0 6 25.0 35 24.0
   No 35 70.0 21 84.0 18 81.8 19 76.0 18 75.0 111 76.0
Sexually transmitted
diseases
   Yes 1 2.0 1 4.0 1 4.5 0 0.0 0 0.0 3 2.1
   No 49 98.0 24 96.0 21 95.5 25 100.0 24 100.0 143 98.0
Hereditary history
   Cancer 23 46.0 13 52.0 7 31.8 13 52.0 9 37.5 65 44.5
   Cervical cancer 3 6.0 1 4.0 1 4.5 4 16.0 2 8.33 11 7.5
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 Figure 1. β-globin gene amplification from the cervical smears: line 1 corresponds to Weight Marker,
2-24 correspond to samples, and 25 to 26 are positive and negative controls, respectively
Figure 2. MYCN gene amplification in cervical smears
from patients with normal cytology, CIN I, CIN II, CIN III,
and cervical cancer
not use any contraception method, 44.5% had a
history of cancer in a family member to the third
degree of consanguinity and of these cases only
7.5% had a history of cervical cancer.
All samples showed a good quality, assessed
by PCR amplification, of β-globin gene (Figure
1).
Genotyping results of the samples are
summarized in Table 3. In general, HPV-positive
patients with normal cytology were 4% for CIN
I 48%, 63.6% CIN II, 64% CIN III and 70.8% in
cervical cancer. Table 3 shows the distribution of
viral types according to the type of injury. Of the
HPV types detected, 83.6% were in the high-risk
group and 16.4% were low-risk HPV types; viral
type 16 was present in 31.6%, followed by HPV
18 with 15.2%, HPV 58 in 13.9%, HPV 31 and 52
with 5%, and HPV 56 with 3.8%. HPV types 33,
35, 42, 45, 59, 66, and 73 were frequent at 2.5%
each, and HPV types 40, 51, 68, 70, and iso39
were found in 1.26% each. In 29.5% of HPV-
positive patients mixed infection was present.
 Regarding the MYCN gene amplification, an
amplification trend was observed in samples
with high-grade lesions compared to those from
normal cytology, they also showed an amplifi-
cation of 8.3% for CIN I, 27% for CIN II, 16% for
CIN III and 39.1% for cancer samples; all
percentages were calculated with respect to
samples from patients with a normal cytology
result (Figure 2). Significant statistical diffe-
rences were observed between groups of normal
cytology and CIN I with respect to the cancer
group with p=0.0005.
For C-MYC, there is no difference of ampli-
fication in samples with some type of CIN or
cancer compared to those from normal cytology,
only a slight gain of 12% for cancer samples
when compared with samples from patients with














Figure 3. C-MYC gene amplification in cervical smears
from patients with normal cytology, CIN I, CIN II, CIN III,
and cervical cancer
significant statistical differences were noted among groups
with p=0.3572.
With respect to the amplification of MYCL1, an
amplification trend was observed in samples with high-grade
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normal cytology and CIN I; they also showed an
amplification of 8.3% for CIN I, CIN II 18%, 16%
for CIN III and 34.7% for cancer samples, all
percentages were calculated with respect to samples
from patients with a normal cytology result (Figure
4). Significant statistical differences were observed
among groups with low-grade lesions compared to
those with high-grade lesions and the cancer group
with p=0.0046.
With ERBB2, amplification was observed mainly
in cancer samples compared to those from normal
cytology and CIN I and CIN II, besides amplification
was observed only in CIN III in 4% and 30.4% of
cancer, all percentages were calculated with respect
to samples from patients with a normal cytology
result (Figure 5). Significant statistical differences
were observed among groups with normal cytology,
CIN I, CIN III, and CIN III with respect to the cancer
group with p=0.001.
In the EGFR gene, a slight tendency for
amplification was observed in samples with high-
grade lesions and cancer compared to those from
normal cytology, they also showed amplification of
9% for CIN I, 14% for CIN II, 13% for CIN III, and
18% for cancer samples; all percentages were
calculated with respect to samples from patients
with normal cytology results (Figure 6). There were
no statistically significant differences among groups
with p=0.071.
In AKT2, although there were no statistically
significant differences (p=0.6166) among groups,
there was a tendency for amplification in high-grade
lesions (CIN II and CIN III) and cervical cancer,
Table 3
Distribution of HPV viral types corresponding to lesion type
          16    18     31    33    35  40    42    45    51   52  56 58    59    66    68   70   73    81  Iso39
Normal
cytology  1  1  1
CIN I  3  2  1  1  1  2  1  4  1  1
CIN II  6  2  2  1  1  1  1  1  1  1
CIN III  3  2  1  1  1  1  5  1  1
Cancer  13  6  1  2  1  2  1
Total  25  12  4  2  2  1  2  2  1  4  3  11  2  2  1  1  2  1  1
Figure 4. MYCL1 Gene amplification in cervical
smears from patients with normal cytology,














Figure 5. ERBB2 Gene amplification in cervical
smears from patients with normal cytology, CIN I,
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with respect to low-grade lesions (CIN I ) and normal
cytology (Figure 7). You can see a 4% gain for CIN I,
5% for CIN II, 8% for CIN III, and 13% for cancer
samples; all percentages were calculated with respect
to samples from patients with a normal cytology result.
Finally, when comparing samples with gene
amplification and the presence of high-risk HPV types,
we found that over 62% of the samples with MYCN,
AKT2, C-MYC or ERBB2 amplification also had high-
risk HPV types. In more than 50% when the genes,
MYCL1 and EGFR were amplified; they also had high-
risk HPV types (Table 4).
 DISCUSSION
In literature, there is great variability of epide-
miological data on the presence of viral DNA in patients
with normal cytology, prevalence ranging from 5.2% in
Spain to 33.3% found in Africa2. The frequency of
HPV found in such patients in this study was 4%,
similar to the 4.6% found by Jacobs et al.9 For patients
with histopathological diagnosis of CIN I, the frequency
we found was 48%, close to what Molano et al.10, found
in 2002, which was 55.7%. For patients with high-
grade lesions: CIN II and CIN III, the present study
found VPH frequencies of 63.6% and 64%, respectively,
similar to what Schiffman and collaborators described,
who found them in 76%10. Finally, in cervical cancer
patients we found a rate of HPV infection of 70.8%,
correlating with what was described by Muñoz et al.2
for Colombia at 74.4%. In the present study, we found
mixed infection in 29.5% of HPV-positive patients,
this correlates with data from Cobo et al.11 where they
observed the presence of mixed infections by 19%.
Gene amplification is an unscheduled aberration
that has been seen only in response to the exposure to
certain cytotoxic drugs and an associated phenomenon
with tumorigenesis4. According to the Cancer Genome
Project at the Sanger Institute12, the genes most
commonly found to be amplified and associated with
cancer are: AKT2, ALK, EGFR, ERBB2, MDM2, Mdm4,
MITF, MYC, MYCL1, MYCN, and REL. In cervical
cancer, a few studies assess gene amplification in
different stages of cervical carcinogenesis, in this case
CIN I, CIN II, and CIN III. In relation to cervical cancer,
gene amplification of EGFR, MYC, and MYCN has
been observed.
Table 4
Percentages by intraepithelial lesion type
with gene amplification and high-risk HPV
                 CIN I      CIN II     CIN III     Cancer
MYCN  100  100  100  90
C-MYC  -  -  -  100
MYCL1  66  50  100  77
ERBB2  -  -  100  62
EGFR  50  66  66  75














Figure 6. EGFR Gene amplification in cervical
smears from patients with normal cytology, CIN I,














Figure 7. AKT2 Gene amplification in cervical
smears from patients with normal cytology, CIN I,
CIN II, CIN III, and cervical cancer
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Analysis of gene amplification can be performed by
FISH, array-CGH, and qPCR; the last used in this study
offers more advantages given its accuracy, lower cost,
speed, ease of interpretation, and because it requires
less DNA. In addition, these three techniques have a
correlation close to 99%5.
Regarding the MYCN gene in samples from patients
with cervical cancer, the present study found an
amplification of 39.1% compared to normal cytology
results, similar to the results by Kinoshita et al.7, who
described MYCN amplified through slot-blot, they
observed amplification up to five times in 40% of 15
cervical cancer samples tested in Japan, suggesting
poor prognosis. However, in another study by Mitra et
al.13, where they evaluated 50 samples of cervical
cancer in India by southern-blot, they did not find
amplification of this gene.
In relation to the status of C-MYC, this was found
amplified in 12% of the samples from cervical cancer
patients, compared to samples from patients with nor-
mal cytology. In samples with lesions of CIN I, CIN II,
and CIN III this gene was not amplified. Nevertheless,
there is a wide divergence of results; for example,
Baker et al.14, found it amplified in 31% of 44 cervical
cancer samples from US patients. Golijow et al.15,
working with 105 patients from Argentina with low-
and high-grade intraepithelial lesions, through qPCR
found amplification of this gene in 17% and 41%,
respectively. On the contrary, Mitra et al.13, found no C-
MYC amplification in cervical cancer samples.
MYCL1 amplification in this study was present in
34.7% of cancer samples compared to samples from
patients with normal cytology. In cervical cancer, a few
studies evaluate MYCL1 amplification in preneoplastic
and neoplastic lesions of the cervix, one of these studies
was conducted by Mitra et al.13, finding this gene
amplified in 2% of 50 samples with cervical cancer.
Nontheless, in other types of tumors such as lymphomas,
there was amplification of this gene in 43% (3 samples
of the 7 tested) by using microarrays16.
Another important oncogene found amplified in
cancer was ERBB2; the present study detected
amplification in 30.4% of the samples from patients
with cervical cancer, values similar to those found by
Sharma et al.17 who observed amplification in 36.6% of
60 samples with cervical cancer assessed by in situ
hybridization and Zhang et al.18 who identified amplifi-
cation in 29% of 84 samples tested by FISH.
In this study, there was amplification of the EGFR
gene in 18% of cervical cancer samples, but few studies
evaluate this gene amplification in cervical cancer and
premalignant lesions. Similar to our results,
Kersemaekers et al.19, in the Netherlands described
EGFR amplification in this type of cancer by Sothern
blot in 12.5% of the 136 cases assessed.
Taking into account that AKT2 has been found
amplified in several types of cancer, including head and
neck in 30% of the 117 patients evaluated from Spain
by qPCR20, the present study found this gene amplified
in 13% of cervical cancer samples; although until now
there are no studies evaluating the amplification of this
gene in cervical cancer or precancerous lesions like
CIN I, CIN II, and CIN III.
According to the results observed when comparing
the presence of high-risk HPV viral types and the
presence of gene amplification, we observed that the
presence of these viral types of HPV might somehow be
related to the susceptibility of gene amplification; given
that it has been observed that HPV infection increases
the risk of genetic instability18. The number of cases
included in this study is too limited to explain the
relationship of such susceptibility. Nowadays few
studies simultaneously evaluate gene amplification and
high-risk HPV viral types. Zhang et al.18 with 90 cervi-
cal cancer patients from Sweden, found a strong
relationship between HPV 16 and / or 18 and gene
amplification of TERT and C-MYC by FISH.. Therefore,
we suggest evaluating these two events in a study
including more cases.
In conclusion, we observed that in general cervical
cancer and high-grade lesions there was greater HPV
frequency and more gene amplification. In addition,
MYCN, ERBB2, and MYCL1 amplification could be
candidates as potential prognostic markers in cervical
cancer, because in high-grade lesions and cancer it is
more common to find these genes amplified with respect
to low-grade lesions. However, it requires a greater
number of cases to corroborate these results.
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